Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBIT Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBIT Margin for 4 consecutive years, with 158.56% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin fell 7458.0% to 158.56% in Q3 2025 year-over-year; TTM through Sep 2025 was 153.2%, a 6407.0% decrease, with the full-year FY2024 number at 95.64%, up 21920.0% from a year prior.
  • EBIT Margin was 158.56% for Q3 2025 at bioAffinity Technologies, up from 198.16% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 171.34% in Q2 2022 to a low of 169160.69% in Q1 2023.
  • A 4-year average of 23846.7% and a median of 150.14% in 2025 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: crashed -918112bps in 2023, then soared 16907986bps in 2024.
  • bioAffinity Technologies' EBIT Margin stood at 69213.21% in 2022, then soared by 100bps to 105.83% in 2023, then dropped by -26bps to 133.47% in 2024, then decreased by -19bps to 158.56% in 2025.
  • Per Business Quant, the three most recent readings for BIAF's EBIT Margin are 158.56% (Q3 2025), 198.16% (Q2 2025), and 141.73% (Q1 2025).